相关实验视频

Updated: Jul 9, 2025

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

在CAR-T细胞中使用CRISPR/Cas9技术进行基因组编辑

Irene Andreu-Saumell¹, Alba Rodriguez-Garcia¹, Sonia Guedan²

¹Department of Hematology and Oncology, Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain.

Methods in molecular biology (Clifton, N.J.)

|December 9, 2023

概括

这项研究详细介绍了CRISPR-Cas9协议用于CAR-T细胞中的基因淘汰,增强它们治疗具有挑战性的癌症的潜力. 该方法使用电穿孔来提高癌症治疗中CAR-T细胞的疗效.

科学领域:

免疫治疗是一种免疫疗法.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

化学抗原受体T细胞 (CAR-T) 疗法对血液性恶性瘤有希望,但在固体瘤和T细胞癌症中面临挑战.
下一代CAR-T细胞需要基因修饰来克服当前的治疗限制.

研究的目的:

描述使用CRISPR-Cas9技术在CAR-T细胞中进行基因淘汰的详细协议.
为了提高CAR-T细胞的疗效和可访问性,用于更广泛的癌症治疗应用.

主要方法:

利用CRISPR-Cas9基因组编辑技术在CAR-T细胞中进行基因淘汰.
专注于核蛋白复合体 (Cas9蛋白和sgRNA) 的电穿孔,以实现简单性,多功能性和减少毒性.
开发了用于淘汰策略设计,CAR-T细胞扩张,基因组编辑和效率分析的协议.

主要成果:

在CAR-T细胞中建立了针对性基因淘汰的强大协议.
通过通过CRISPR-Cas9.9进行基因修饰来增强CAR-T细胞功能的可行性.
验证了用于CAR-T细胞基因组编辑的电穿孔方法的效率.

结论:

克里斯普尔-Cas9技术,特别是通过核糖蛋白电穿孔,为工程先进的CAR-T细胞提供了一个可行的策略.
该协议有助于开发更有效的CAR-T细胞疗法来治疗各种癌症,包括固体瘤和T细胞恶性瘤.
描述的方法支持CAR-T细胞基因编辑策略的设计和分析,以改善治疗结果.

关键词:

在CAR-T细胞中.这就是CRISPR/Cas9的作用.基因组编辑基因组编辑工程T细胞工程T细胞工程

更多相关视频

Production of Human CRISPR-Engineered CAR-T Cells

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells

Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells

Published on: September 25, 2019

相关概念视频

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...

CRISPR and crRNAs

CRISPR and crRNAs

Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...